Ahren Innovation Capital

Ovo Labs is a biotechnology company focused on improving in vitro fertilization (IVF) success rates. It develops therapeutics that enhance egg quality, aiming to extend the window of opportunity for successful conception, particularly for women facing age-related fertility challenges.

Constructive Bio is a biotechnology company that rewrites genomes to turn living cells into biofactories for sustainable materials and therapeutics. By controlling the genetic sequence, it enables the biosynthesis of enzymes, pharmaceuticals, and biomaterials while exploring chemical space beyond natural biology. The approach includes developing virus-resistant organisms and supporting next-generation bioprocesses and biopharmaceuticals.

ZOE is a personalized nutrition company that focuses on improving individual health through a comprehensive understanding of the complex relationships between food, lifestyle, and health. It operates the world's largest nutrition-science study, as well as the ZOE Health Study, which initially addressed the impacts of COVID-19. The company offers at-home testing kits that assess gut health, blood fat, and blood sugar responses, providing personalized dietary recommendations based on individual reactions to food. Users receive tailored advice through an integrated mobile application, which includes food scores and guidance for making healthier dietary choices over a four-week period. ZOE's research is grounded in the understanding that gut bacteria significantly influence health, and its findings have been published in prestigious peer-reviewed journals. Through its innovative approach, ZOE aims to empower individuals to enhance their well-being and adopt healthier lifestyles.

Mentee Robotics develops AI-powered humanoid robots designed to adapt to various environments and tasks. Their robots combine robotics, sensing, and artificial intelligence to mimic human dexterity and perception, aiming to enhance productivity in households and warehouses.

Sunfire is a company that specializes in developing and manufacturing systems for renewable industrial gas and fuel production. It focuses on creating substitutes for fossil fuels, such as mineral oil and natural gas, through innovative technologies like electrolyzers and solid oxide cells. These systems convert renewable electrical energy from sources like wind farms, hydropower plants, and photovoltaic systems into fuels and gases, including renewable hydrogen and syngas. By enabling the chemical, fuel, and steel industries to transition away from fossil energy, Sunfire aims to provide sustainable energy solutions that are available whenever needed, thus integrating renewable energy into existing infrastructures.

Mogrify develops proprietary platform technologies that enable direct cellular reprogramming. These platforms use big-data approaches to predict transcription factors and growth factors required for producing any target human cell type from any source human cell type. Mogrify applies these platforms to generate functional cell types for in vivo reprogramming therapies, focusing on ophthalmology, otology, metabolic diseases, and other degenerative conditions.

ZOE is a personalized nutrition company that focuses on improving individual health through a comprehensive understanding of the complex relationships between food, lifestyle, and health. It operates the world's largest nutrition-science study, as well as the ZOE Health Study, which initially addressed the impacts of COVID-19. The company offers at-home testing kits that assess gut health, blood fat, and blood sugar responses, providing personalized dietary recommendations based on individual reactions to food. Users receive tailored advice through an integrated mobile application, which includes food scores and guidance for making healthier dietary choices over a four-week period. ZOE's research is grounded in the understanding that gut bacteria significantly influence health, and its findings have been published in prestigious peer-reviewed journals. Through its innovative approach, ZOE aims to empower individuals to enhance their well-being and adopt healthier lifestyles.

Ambi Robotics develops AI-powered robotics solutions to scale e-commerce operations and assist human workers. The company provides adaptable automation tools for supply chain tasks, including a put wall, configurable and modular kitting line, and a simulation-to-reality operating system designed to improve accuracy and efficiency while reducing operating costs. Based in Berkeley, California, Ambi Robotics focuses on applying intelligent automation to warehouse processes to help businesses meet demand.

Constructive Bio is a biotechnology company that rewrites genomes to turn living cells into biofactories for sustainable materials and therapeutics. By controlling the genetic sequence, it enables the biosynthesis of enzymes, pharmaceuticals, and biomaterials while exploring chemical space beyond natural biology. The approach includes developing virus-resistant organisms and supporting next-generation bioprocesses and biopharmaceuticals.

Phaidra, Inc. is a Seattle-based company established in 2019 that specializes in designing and developing artificial intelligence solutions for industrial sectors in the United States. The company focuses on providing AI and machine learning technologies aimed at enhancing performance in large-scale facilities. Phaidra's offerings include a virtual plant operator service that utilizes closed-loop AI control to empower operations teams in mission-critical environments. By analyzing extensive sensor data, Phaidra creates intelligent agents that automatically optimize and manage complex industrial processes. This innovative approach helps clients improve energy efficiency, increase safety and stability, and maximize operational yield, contributing to greater sustainability in their operations.

AI21 Labs is an Israeli artificial intelligence company that develops generative AI and large language models along with tools to understand and generate natural language. Founded in 2017 and based in Tel Aviv-Yafo, it provides AI-based writing and reading assistance that understands context and meaning, including a writing companion that can rephrase text to convey the intended message and generate summaries. The company's tools help users read more efficiently, analyze and visualize complex knowledge structures, and apply deep learning and NLP to transform writing and comprehension for businesses and individuals.

Bitfount is a comprehensive platform facilitating secure collaboration in data science and AI projects. It enables organizations to work together on sensitive data without actually sharing it, employing federated learning and other privacy-preserving techniques.

Heirloom is a carbon capture company developing direct air capture technology that accelerates the natural absorption of carbon dioxide. Its approach uses a limestone-based process to increase CO2 uptake and stores the captured carbon permanently underground, powered by renewable energy. The company also applies carbon capture and utilization techniques to enhance natural CO2 removal. By offering a scalable, renewable-energy driven solution, Heirloom aims to help businesses meet sustainability goals with a cost-effective path to significant carbon removal.

OxDX is a spinout that combines the power of single-molecule fluorescent microscopy with machine learning to identify pathogens in under a minute. They use a universal labelling system to light up everything in our sample, image the sample using super-resolution fluorescence microscopy, and analyse the images in our neural network.

Micropsi Industries GmbH is a Berlin-based robotics software company founded in 2014, specializing in machine learning solutions for robotics and process control. The company develops MIRAI, an advanced robot control system designed for complex assembly tasks. MIRAI enables robots to perform movements that adapt to subtle changes in their environment, utilizing cameras and force sensors. Unlike traditional programming methods, MIRAI's capabilities are acquired through a process of demonstration, correction, and repetition, allowing users to train robots without the need for coding or problem modeling. This innovative approach enhances productivity, ergonomics, and resilience in industrial settings, making it easier for businesses to automate tasks that were previously deemed too complex.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.

ZOE is a personalized nutrition company that focuses on improving individual health through a comprehensive understanding of the complex relationships between food, lifestyle, and health. It operates the world's largest nutrition-science study, as well as the ZOE Health Study, which initially addressed the impacts of COVID-19. The company offers at-home testing kits that assess gut health, blood fat, and blood sugar responses, providing personalized dietary recommendations based on individual reactions to food. Users receive tailored advice through an integrated mobile application, which includes food scores and guidance for making healthier dietary choices over a four-week period. ZOE's research is grounded in the understanding that gut bacteria significantly influence health, and its findings have been published in prestigious peer-reviewed journals. Through its innovative approach, ZOE aims to empower individuals to enhance their well-being and adopt healthier lifestyles.

Adrestia Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2017. The company specializes in developing therapeutics aimed at restoring the biological balance in damaged, diseased, and dying cells. Adrestia Therapeutics is recognized for its expertise in synthetic rescue, an innovative approach that decodes complex genetic networks to identify novel treatment strategies for various diseases. In addition to therapeutic development, the company provides basic and applied research, as well as experimental development services tailored to the biotechnology industry.

Nu Quantum Ltd is a company focused on developing quantum photonics hardware and quantum networking infrastructure to enhance the capabilities of quantum computing. Established in 2018 and based in Cambridge, United Kingdom, the company specializes in creating photon sources, detectors, and systems for quantum cryptography. Nu Quantum's innovations include nano-engineered materials for the generation of light at the quantum level and ultra-sensitive light detection systems. The company aims to establish the necessary infrastructure for interconnecting quantum computing cores into large distributed clusters, which is essential for scaling quantum computers. By developing full hardware solutions, including high-speed network interfaces and photonic switching fabrics, Nu Quantum seeks to facilitate the creation of entangled qubit networks. The company collaborates with leading quantum computing firms, governments, and research institutions to bring its advanced technologies to market, focusing on secure cryptographic key exchange and the future of information processing.

Rockley Photonics Limited, founded in 2013 and based in London, United Kingdom, specializes in developing silicon photonics technologies for diverse applications. The company focuses on creating integrated optical modules, sensors, and comprehensive solutions that cater to high-volume and dynamic market sectors. Rockley aims to revolutionize mobile health monitoring and machine vision with its next-generation sensing platforms, while also providing high-speed solutions for data communications. By leveraging its innovative photonic integrated circuits and associated modules, Rockley is positioned to address a wide array of vertical applications, believing that photonics will become as ubiquitous as microelectronics in the future. The company combines hardware with supporting electronics, software, application algorithms, and AI platforms, establishing a robust foundation for future developments across multiple industries.

Graphcore is a hardware systems company that develops intelligent processing units to accelerate machine learning. It designs IPUs and offers IPU-Accelerator cards that plug into servers to accelerate training and inference, and IPU-Appliance products that deliver higher performance for inference and training workloads. Founded in 2016 and headquartered in Bristol, United Kingdom, the company maintains additional locations in Palo Alto, London, Oslo, and Beijing. Its IPU architecture enables running current machine learning models orders of magnitude faster across various servers and processors, supporting a range of AI workloads.

Nu Quantum Ltd is a company focused on developing quantum photonics hardware and quantum networking infrastructure to enhance the capabilities of quantum computing. Established in 2018 and based in Cambridge, United Kingdom, the company specializes in creating photon sources, detectors, and systems for quantum cryptography. Nu Quantum's innovations include nano-engineered materials for the generation of light at the quantum level and ultra-sensitive light detection systems. The company aims to establish the necessary infrastructure for interconnecting quantum computing cores into large distributed clusters, which is essential for scaling quantum computers. By developing full hardware solutions, including high-speed network interfaces and photonic switching fabrics, Nu Quantum seeks to facilitate the creation of entangled qubit networks. The company collaborates with leading quantum computing firms, governments, and research institutions to bring its advanced technologies to market, focusing on secure cryptographic key exchange and the future of information processing.

Mogrify develops proprietary platform technologies that enable direct cellular reprogramming. These platforms use big-data approaches to predict transcription factors and growth factors required for producing any target human cell type from any source human cell type. Mogrify applies these platforms to generate functional cell types for in vivo reprogramming therapies, focusing on ophthalmology, otology, metabolic diseases, and other degenerative conditions.

6D.ai is a technology company specializing in the development of application programming interfaces for the augmented reality (AR) industry. Founded in 2017 and headquartered in San Francisco, California, the company focuses on creating a robust AR cloud platform that enables real-time, three-dimensional mapping of the environment using data sourced from standard smartphone cameras and mobile sensors. Its technology facilitates the construction of dense, interactive 3D meshes, allowing for multi-user AR experiences and enhancing spatial computing capabilities. By leveraging crowdsourced data, 6D.ai's solutions empower developers to create applications that seamlessly integrate with the physical world, thereby enriching user engagement and interaction. As of March 2020, 6D.ai operates as a subsidiary of Niantic, Inc.

Mogrify develops proprietary platform technologies that enable direct cellular reprogramming. These platforms use big-data approaches to predict transcription factors and growth factors required for producing any target human cell type from any source human cell type. Mogrify applies these platforms to generate functional cell types for in vivo reprogramming therapies, focusing on ophthalmology, otology, metabolic diseases, and other degenerative conditions.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

Adrestia Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2017. The company specializes in developing therapeutics aimed at restoring the biological balance in damaged, diseased, and dying cells. Adrestia Therapeutics is recognized for its expertise in synthetic rescue, an innovative approach that decodes complex genetic networks to identify novel treatment strategies for various diseases. In addition to therapeutic development, the company provides basic and applied research, as well as experimental development services tailored to the biotechnology industry.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.